Fifth Third Bank to Decrease Prime Lending Rate to 8.00%
CINCINNATI--(BUSINESS WIRE)-- Fifth Third Bank, National Association, today announced it will decrease its prime lending rate to 8.00%, effective immediately.
The rate was last changed on July 26, 2023, when Fifth Third increased its prime lending rate from 8.25% to 8.50%
About Fifth Third
Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation’s highest performing regional bank, but to be the bank people most value and trust.
Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank, and its common stock is traded on the NASDAQ® Global Select Market under the symbol "FITB." Investor information and press releases can be viewed at www.53.com.
Category: Other
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918243478/en/
Adrienne Gutbier (Media Relations)
[email protected] | 513-534-8038
Matt Curoe (Investor Relations)
[email protected] | 513-534-2345
Source: Fifth Third Bank
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gold Reserve Announces Intention to Make Further CVR/Bonus Settlement Offers, to Make Offers to Optionholders, and to Amend Equity Incentive Plan
- U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multip
- Tier One Silver Announces C$12 - C$17 Million Financing to Fund Ruta de Cobre Acquisition and Exploration
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share